Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10760719 | 0.87 | APP (0.53) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8817680 | 0.87 | APP (0.53) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL4205280 | 0.84 | APP (0.52) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL10979841 | 0.84 | APP (0.50) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8755138 | 0.82 | APP (0.78) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL10704177 | 0.82 | APP (0.60) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11499580 | 0.82 | APP (0.60) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL3938352 | 0.82 | APP (0.78) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11038666 | 0.81 | APP (0.47) | APPAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL7325024 | 0.81 | APP (0.58) | APPAKR1C3AKR1C2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4324904-A | COMPOUND USEFUL IN MAKING FLURBIPROFEN | THE UPJOHN COMPANY (US) | 1982-04-13 | — | — | US | claimed |
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-07-02 | — | — | US | disclosed |
| WO-2014015341-A2 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | VANDERBILT UNIVERSITY (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
| CN-1138764-C | Isoxazole derivatives | ס����ҩ��ʽ���� | 2004-02-18 | — | — | CN | disclosed |
| CN-1252794-A | Isoxazole derivatives | SUMITOMO PHARMA (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5180731-A | Treatment of autoimmune diseases, lipoxygenase inhibitor | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-01-19 | — | — | US | disclosed |
| US-5066666-A | Treatment Of Autoimmune Diseases, E.G. Rheumatoid Arthritis | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-11-19 | — | — | US | disclosed |
| US-4914112-A | TREATMENT OF AUTOIMMUNE DISEASES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0123629-B1 | PREPARATION OF BIARYL COMPOUNDS | ETHYL CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0248399-A1 | Aminoazole derivatives and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183737-A1 | COMPOSITIONS AND METHODS FOR SUBSTRATE-SELECTIVE INHIBITION OF ENDOCANNABINOID OXYGENATION | CNR2, FAAH2, FAAH | APP 2009/4885AKR1C3 729/4885AKR1C2 821/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | APP 1/4885AKR1C3 570/4885AKR1C2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.